• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Affimed Therapeutics

edit

Affimed Therapeutics AG, a biopharmaceutical company, engages in the discovery and development of recombinant antibody therapeutics for the treatment of cancer and other diseases. It offers TandAbs, a tetravalent antibody that is targeting tumor cells. The company also provides programs for treatment of Non-Hodgkin’s Lymphoma, Hodgkin’s diseases, thrombosis and autoimmune, leukemia, myeloma, solid tumors, metastasis, non-cancer indications, allergy, and asthma diseases. Affimed Therapeutics AG was founded in 2000 and is headquartered in Heidelberg, Germany.

Recent Milestones

edit

• 
  Affimed Therapeutics received $26.5M (€20M) in Series C funding. (4/29/10)
  Posted 5/4/10 at 11:05pm via fiercebiotech.com
• 
  Affimed Therapeutics added Rolf H. Günther as CEO.
  Posted 5/4/10 at 11:05pm
• 
  Affimed Therapeutics added Florian Fischer as CFO.
  Posted 5/4/10 at 11:05pm

Videos

Screenshots

edit

Sources

1. Affimed raises €20M to fund innovative antibody trials (fiercebiotech.com) [edit]